Oral treatment of erectile dysfunction with apomorphine SL
- PMID: 11741126
- DOI: 10.1159/000051001
Oral treatment of erectile dysfunction with apomorphine SL
Abstract
Apomorphine SL (Ixense, Uprima) is a new oral medication shown to be effective in the treatment of erectile dysfunction. This compound is a dopaminergic agonist with affinity for dopamine receptor sites - mostly D(2) - within the brain known to be involved in sexual function. Apomorphine induces selective activation in the nucleus paraventricularis leading to erectogenic signals. More than 5,000 men with erectile dysfunction participated in phase II/III clinical trials assessing the safety and efficacy of doses ranging from 2 to 6 mg. The most favorable risk/benefit ratio is seen with a dose-optimization regimen of 2-3 mg: the 3-mg dose provides efficacy comparable to that of 4 mg but with fewer side effects. Consequently, review of clinical studies focuses on data with the 2- to 3-mg dose, the registered dose for use in clinical practice. The primary efficacy endpoint in most clinical trials with apomorphine SL was the percentage of attempts resulting in erections firm enough for intercourse - one of the most rigorous endpoints used in ED trials to date. These data were collected from both patients and their partners by reviewing entries in patient diaries and partner BSFI questionnaires. Secondary endpoints included percentage of attempts resulting in intercourse and improvement in ED severity based on the International Index of Erectile Function (IIEF). The proportion of attempts resulting in erections firm enough for intercourse was 49.4% with 3 mg compared with the baseline value of 24.3%. Partner evaluations corresponded with those of the patients. Erections occurred between 18 and 19 min after taking apomorphine SL 2 or 3 mg. The most common side effect was nausea which declined with continued use. Vasovagal syncope was reported in <0.2% of men, and was preceded by clear prodromal symptoms. Thus, apomorphine SL is an effective, well-tolerated drug for erectile dysfunction.
Copyright 2001 S. Karger AG, Basel
Similar articles
-
An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.Clin Ther. 2001 Aug;23(8):1260-71. doi: 10.1016/s0149-2918(01)80105-3. Clin Ther. 2001. PMID: 11558862 Clinical Trial.
-
A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.BJU Int. 2002 Mar;89(4):409-15. doi: 10.1046/j.1464-4096.2001.01453.x. BJU Int. 2002. PMID: 11872034 Clinical Trial.
-
Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.Eur Urol. 2001 May;39(5):558-3; discussion 564. doi: 10.1159/000052503. Eur Urol. 2001. PMID: 11464037 Clinical Trial.
-
Sublingual apomorphine for the treatment of erectile dysfunction.Expert Opin Investig Drugs. 2002 Feb;11(2):295-302. doi: 10.1517/13543784.11.2.295. Expert Opin Investig Drugs. 2002. PMID: 11829718 Review.
-
Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective.Int J Impot Res. 2001 Aug;13 Suppl 3:S29-34. doi: 10.1038/sj.ijir.3900720. Int J Impot Res. 2001. PMID: 11477489 Review.
Cited by
-
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.Asian J Pharm Sci. 2018 Nov;13(6):507-517. doi: 10.1016/j.ajps.2017.11.004. Epub 2017 Dec 6. Asian J Pharm Sci. 2018. PMID: 32104425 Free PMC article. Review.
-
Ethnopharmacology of Love.Front Pharmacol. 2018 Jul 3;9:567. doi: 10.3389/fphar.2018.00567. eCollection 2018. Front Pharmacol. 2018. PMID: 30026695 Free PMC article. Review.
-
Aberrant baseline brain activity in psychogenic erectile dysfunction patients: a resting state fMRI study.Brain Imaging Behav. 2018 Oct;12(5):1393-1404. doi: 10.1007/s11682-017-9805-9. Brain Imaging Behav. 2018. PMID: 29243122 Free PMC article.
-
Aberrant Insula-Centered Functional Connectivity in Psychogenic Erectile Dysfunction Patients: A Resting-State fMRI Study.Front Hum Neurosci. 2017 May 16;11:221. doi: 10.3389/fnhum.2017.00221. eCollection 2017. Front Hum Neurosci. 2017. PMID: 28559803 Free PMC article.
-
Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders.CNS Neurosci Ther. 2010 Jun;16(3):e92-123. doi: 10.1111/j.1755-5949.2010.00154.x. CNS Neurosci Ther. 2010. PMID: 20557568 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical